ABT-737 synergizes with Bortezomib to kill melanoma cells.

Biol Open · 2012 · PMC3507205 · PMID 23213401

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

These changes were highly significant statistically, and demonstrate that Mcl-1 is the critical factor for melanoma resistance to ABT-737.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.